December 25, 2018
China’s I-Mab biopharma gets USFDA’s approval for IND application for TJM2
A China-based clinical stage biopharmaceutical immuno-oncology and autoimmune diseases focused company, I-Mab Biopharma (I-Mab), said Monday it got the US Food and Drug Administration (FDA) has approval for its IND application for TJM2, a potential treatment for autoimmune and inflammatory diseases.